Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
REGULATORY
MHLW Working Group to Kick Off Discussions on Guidelines to Address Elderly Polypharmacy
A working group of the Ministry of Health, Labor and Welfare (MHLW) plans to hold its first meeting on September 1 to discuss guidelines to counter polypharmacy in the elderly after its upper organ agreed on their creation last month.…
To read the full story
Related Article
- MHLW Study Group Approves Framework for Comprehensive Guidelines on Pharmacotherapy in the Elderly
January 9, 2018
- MHLW Working Group to Draw Up Elderly Polypharmacy Guidelines in 2 Stages
September 4, 2017
- MHLW Panel Agrees to Compile Guidelines to Address Polypharmacy in the Elderly
July 18, 2017
- MHLW Calls for Drafting Guidelines on Polypharmacy in the Elderly
June 27, 2017
- New MHLW Panel Starts Discussions on Proper Drug Use Guidelines for Elderly; Final Report Expected by End of FY2018
April 19, 2017
REGULATORY
- MOF Presses for Full FY2027 Drug Price Revision Without Price Gap Thresholds
November 4, 2026
- Japan Panel to Review Kyowa Kirin’s Libmeldy for Approval on Nov. 9
November 4, 2026
- PMDA Sets Out AI Principles for Regulatory Activities, Stresses Human Oversight
November 4, 2026
- Public-Private Pharma Talks Expand to Domestic R&D, Manufacturing Investment
November 2, 2026
- Japan’s Healthcare Spending Hits Record 48.8 Trillion Yen in FY2024
November 2, 2026
Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…